BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27187622)

  • 1. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies.
    Sallman DA; Padron E
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):89-95. PubMed ID: 27187622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
    Kubesova B; Pavlova S; Malcikova J; Kabathova J; Radova L; Tom N; Tichy B; Plevova K; Kantorova B; Fiedorova K; Slavikova M; Bystry V; Kissova J; Gisslinger B; Gisslinger H; Penka M; Mayer J; Kralovics R; Pospisilova S; Doubek M
    Leukemia; 2018 Feb; 32(2):450-461. PubMed ID: 28744014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic biomarkers in myeloid malignancies.
    Matynia AP; Szankasi P; Shen W; Kelley TW
    Arch Pathol Lab Med; 2015 May; 139(5):594-601. PubMed ID: 25152312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.
    Patel B; Hirsch C; Clemente M; Sekeres M; Makishima H; Maciejewski JP
    Int J Hematol; 2015 Mar; 101(3):213-8. PubMed ID: 25690487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
    Vantyghem S; Peterlin P; Thépot S; Ménard A; Dubruille V; Debord C; Guillaume T; Garnier A; Le Bourgeois A; Wuilleme S; Godon C; Theisen O; Eveillard M; Delaunay J; Maisonneuve H; Morineau N; Villemagne B; Vigouroux S; Subiger F; Lestang E; Loirat M; Parcelier A; Godmer P; Mercier M; Trebouet A; Luque Paz D; Le Calloch R; Le Clech L; Bossard C; Moreau A; Ugo V; Hunault M; Moreau P; Le Gouill S; Chevallier P; Béné MC; Le Bris Y
    Haematologica; 2021 Mar; 106(3):701-707. PubMed ID: 32241844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
    Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
    Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fishing the targets of myeloid malignancies in the era of next generation sequencing.
    Shi X; He BL; Ma AC; Leung AY
    Blood Rev; 2016 Mar; 30(2):119-30. PubMed ID: 26443083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCC3 mutations in myeloid neoplasms.
    Huang D; Nagata Y; Grossmann V; Radivoyevitch T; Okuno Y; Nagae G; Hosono N; Schnittger S; Sanada M; Przychodzen B; Kon A; Polprasert C; Shen W; Clemente MJ; Phillips JG; Alpermann T; Yoshida K; Nadarajah N; Sekeres MA; Oakley K; Nguyen N; Shiraishi Y; Shiozawa Y; Chiba K; Tanaka H; Koeffler HP; Klein HU; Dugas M; Aburatani H; Miyano S; Haferlach C; Kern W; Haferlach T; Du Y; Ogawa S; Makishima H
    Haematologica; 2015 Aug; 100(8):1051-7. PubMed ID: 26001790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
    Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
    J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of myeloid malignancies: pathogenetic and clinical implications.
    Fröhling S; Scholl C; Gilliland DG; Levine RL
    J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
    Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
    J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
    Au CH; Wa A; Ho DN; Chan TL; Ma ES
    Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
    Harada Y; Harada H
    Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
    Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
    J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.
    Alawieh D; Cysique-Foinlan L; Willekens C; Renneville A
    Blood Cancer J; 2024 Apr; 14(1):72. PubMed ID: 38658558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
    Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
    Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies.
    Öz Puyan F; Alkan S
    Balkan Med J; 2019 Feb; 36(2):78-87. PubMed ID: 30251956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.